1/6
09:02 am
ghrs
GH Research (NASDAQ:GHRS) was given a new $29.00 price target on by analysts at Needham & Company LLC.
High
Report
GH Research (NASDAQ:GHRS) was given a new $29.00 price target on by analysts at Needham & Company LLC.
1/6
08:42 am
ghrs
GH Research (NASDAQ:GHRS) was given a new $39.00 price target on by analysts at Wolfe Research.
High
Report
GH Research (NASDAQ:GHRS) was given a new $39.00 price target on by analysts at Wolfe Research.
1/6
08:42 am
ghrs
GH Research (NASDAQ:GHRS) was given a new $39.00 price target on by analysts at Canaccord Genuity Group Inc..
High
Report
GH Research (NASDAQ:GHRS) was given a new $39.00 price target on by analysts at Canaccord Genuity Group Inc..
1/6
07:07 am
ghrs
GH Research (NASDAQ:GHRS) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
GH Research (NASDAQ:GHRS) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
1/5
02:10 pm
ghrs
GH Research (NASDAQ:GHRS) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
GH Research (NASDAQ:GHRS) had its "buy" rating reaffirmed by analysts at Cowen Inc.
1/5
11:07 am
ghrs
GH Research (NASDAQ:GHRS) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
GH Research (NASDAQ:GHRS) had its "buy" rating reaffirmed by analysts at Guggenheim.
1/5
08:02 am
ghrs
GH Research (NASDAQ:GHRS) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.
High
Report
GH Research (NASDAQ:GHRS) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.
1/5
07:54 am
ghrs
GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026 [Yahoo! Finance]
High
Report
GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026 [Yahoo! Finance]
1/5
07:00 am
ghrs
GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026
Low
Report
GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026
1/4
08:31 am
ghrs
GH Research: GH001 Shows Robust Data Ahead Of FDA IND Decision [Seeking Alpha]
Medium
Report
GH Research: GH001 Shows Robust Data Ahead Of FDA IND Decision [Seeking Alpha]
1/2
04:26 pm
ghrs
GH Research to Announce IND Status for GH001 [Yahoo! Finance]
Medium
Report
GH Research to Announce IND Status for GH001 [Yahoo! Finance]
1/2
04:01 pm
ghrs
GH Research to Announce IND Status for GH001
High
Report
GH Research to Announce IND Status for GH001
11/10
12:53 pm
ghrs
GH Research (NASDAQ:GHRS) had its price target lowered by analysts at HC Wainwright from $40.00 to $35.00. They now have a "buy" rating on the stock.
Low
Report
GH Research (NASDAQ:GHRS) had its price target lowered by analysts at HC Wainwright from $40.00 to $35.00. They now have a "buy" rating on the stock.
11/8
01:18 pm
ghrs
Low
Report
11/6
07:23 am
ghrs
GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
Low
Report
GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
11/6
07:00 am
ghrs
GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates
Low
Report
GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates